D2C7-IT With Atezolizumab for Recurrent Gliomas
D2C7-IT With Atezolizumab for Recurrent Gliomas
Active, not recruiting · NCT04160494 · Registry updated 2026-06-17Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| D2C7-IT With Atezolizumab for Recurrent Gliomas | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, astrocytoma (excluding glioblastoma), epithelial neoplasm, glioblastoma, glioma, malignant glioma, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor | Active, not recruiting | Phase 1 | 2026-06-17 | NCT04160494 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Darell Bigner | 5 |
| Genentech, Inc. | 221 |
| Istari Oncology, Inc. | 2 |
| National Cancer Institute (NCI) | 3015 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Duke University Medical Center | Durham | United States | 505 |